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Abstract
Many drugs have unknown, controversial or multiple mechanisms of action. Four recent ‘chemical
genomic’ studies, using genome-scale collections of yeast gene deletions that were either arrayed
or barcoded, have presented complementary approaches to identifying gene-drug and pathway-
drug interactions. 
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The fact that much of modern drug research is target-oriented
obscures the long history during which the effects of drugs
were discovered prior to identification of their targets. There
remain many natural products and drugs for which the cellular
target protein(s) are yet to be fully characterized. Without the
identification of specific targets, it is extremely difficult to
modify and improve the performance of drugs and to deter-
mine whether side effects are due to effects on the primary
target or ‘off target’ effects. Indeed, mouse-on-the-hotplate
analgesia assays [1] seem crude in this era of high-throughput
screening and structure-based refinement of, for example,
inhibitors of cyclooxygenase 2 (COX-2) [2]. But the advantage
of targetless whole-animal assays is that compounds that
would pass some early stage of in vitro screening, only later
to fail to have in vivo efficacy, do not score positively in
whole-animal assays. This is important because acceleration
of failure is considered to be a cost- and time-conserving
necessity in drug discovery. 
There is clearly a need to work through the legacy compound
collections owned by pharmaceutical companies. In addition,
the introduction of zebrafish [3] and invertebrate [4]
systems into drug screening (for the advantages cited above
for mouse assays) will ensure that there is an ongoing need
for genetic and genomic strategies that can identify the
targets of pharmacologically interesting small molecules.
Because no eukaryotic model system is more genetically
advanced than the budding yeast Saccharomyces cerevisiae
and because fungi contain substantial numbers of orthologs
of human drug targets, baker’s yeast is an obviously place to
start to identify drug mechanisms of action. Four recent
papers [5-8] make important contributions to mapping drug
effects using yeast genomics. 
The genetic basis of drug sensitivity and
resistance 
Before reviewing recent work, it is useful to consider a
number of ways in which a drug might inhibit the division,
growth or survival of yeast cells. Conceptually, the simplest
mechanism is that a drug inhibits an enzyme essential for
cell division and growth, such as a replicative DNA polymerase.
If this were the case, then the primary target of the drug is
expected to be encoded by an essential gene, such that one
could select for dominant resistant mutants in haploid or
diploid cells; but one could not easily conduct a screen that
would depend on recovery of haploid loss-of-function
mutants in the target gene because such cells are expected to
be nonviable. Because a collection of all potential dominant
mutants would have many more members than the total
number of genes (and, in fact, many more than the total
number of codons), there is no standing genetic resource for
such drug selections in any organism. Typically, a researcher
interested in selecting for dominant drug-resistant mutants
will mutagenize cells anew and plate many millions of such
cells for resistant colonies.
In the case of replicative polymerases, many drugs that act
on these proteins are actually pro-drugs, compounds that
depend on cellular enzymes for conversion to the activeinhibitory agents. Thus, for azidothymidine or dideoxyinosine
to inhibit their intended targets (reverse transcriptases) or
their unintended targets (host DNA polymerases), the
compounds must undergo three cycles of phosphorylation to
generate chain-terminating nucleoside triphosphates. For
cases in which pro-drug activation is limiting for toxicity,
simple loss-of-function mutations in pro-drug activation
enzymes are expected to cause drug resistance, unless the
enzymes are encoded by essential genes, while supersensitive
mutants might be identified as specific gain-of-function alleles
of pro-drug activating enzymes. The ability to select a resistant
mutant as a simple loss-of-function allele is a tremendous
advantage because the necessary mutagenized library size
becomes equal to the number of nonessential genes. 
Identifying drug-sensitive mutants from libraries of loss-
of-function mutants has been facilitated by the preparation
of nearly complete collections of yeast gene knockouts. For
drug screens in which one wishes to query only nonessential
genes, haploid yeast libraries can be used that will ultimately
number around 5,000 strains, each carrying a deletion of a
single nonessential gene. Typically, the gene-drug interactions
that are discovered from such screens do not point directly
to the target of the drug being screened but rather to a
second cellular process that is rendered essential by treatment
with a drug. By contrast, for drug screens in which one
would like to embrace the full complement of nonessential
and essential genes, libraries of yeast heterozygous diploid
strains can be utilized that will ultimately number more than
6,000. Screening such heterozygous libraries typically
identifies the drug target by a process termed drug-induced
haploinsufficiency [9], but titration of a target by a drug may
also render another gene or pathway ‘synthetically’ lethal.
Genetic arraying and barcoding 
Historically, experiments that positively select for features of
interest have been considered to be more powerful than
simple mutant screens because more cells can be plated in a
selection (for colony formation against a background of drug
sensitivity) than in a screen (failure to grow against a back-
ground of growth). The problem is recovering and identifying
the most sensitive strains from screens. There are two practical
approaches to this problem: genetic arraying [5,6] and
barcoding [7,8], which are schematized in Figure 1. In a
genetic arraying experiment, thousands of strains of different
genotypes are maintained in ordered grids and transferred
to drug plates, typically by robotic transfer. This approach
was first utilized in genome-scale two-hybrid [10] and
synthetic-lethal analyses [11]. While the genetic array may
be at a genomic scale, I prefer the term ‘genetic array’ to
‘genomic array’, to avoid confusion with expression arrays
and to emphasize that the arrayed elements are mutant
strains. Alternatively, in a barcoding experiment, a genome-
scale deletion library is treated as a single pool. Because, in
the construction of the collection of yeast gene deletions,
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Figure 1
Genetic arrays and barcodes for chemical genomics. (a) In a genetic array,
constructed mutants are maintained separately and are stamped onto
no-drug or drug-containing petri dishes for time-dependent photographic
analysis. (b) In a barcoding experiment, mutants are pooled and grown
together with and without drugs. Growth of each of the mutants is assessed
by hybridization of amplified barcodes to a microarray (the barcodes are
labeled with Cy3 or Cy5 fluorescent dyes). Because particular mutant strains
may have drug-free growth defects and/or lower barcode microarray signal
efficiency, drug sensitivity or resistance can only be scored for a particular
strain in comparison to its behavior without a drug. 
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Cy5 barcode PCRoligonucleotide ‘barcodes’ were integrated next to each
deletion and flanked by common PCR-primer annealing
sites [12,13], loss of a strain heterozygous for a particular
gene can be measured by loss of signal in a DNA microarray
using a barcode oligonucleotide chip [9]. The barcode
microarray is not an expression array but rather a microarray
performed to quantify introduced DNA elements in the
mixed population of strains. Both genetic arrays and barcoding
have recently been used to identify drug targets using yeast.
Sensitivity of tryptophan auxotrophs to ibuprofen 
Using a genetic-array-based method, Tucker and Fields [5]
investigated the sensitivity of 4,800 haploid yeast strains,
each containing a deletion of a different gene, to ibuprofen
and three other drugs. After removing strains considered too
sick for scoring drug effects and those that were sensitive to
multiple drugs, the authors found a number of interesting
gene-drug and pathway-drug interactions. Ibuprofen is
widely used as a nonsteroidal anti-inflammatory drug
(NSAID) that inhibits cyclooxygenase. The NSAIDs ibuprofen,
indomethacin and sulindac sulfide, however, have been
reported to reduce Alzheimer’s disease and amyloidogenesis
in a manner that does not involve cyclooxygenase [14], and it
appears that the cancer chemopreventive effects of NSAIDs
are not entirely due to cyclooxygenase inhibition [15]. As
yeast cells do not encode a cyclooxygenase but 50 M
ibuprofen is growth-inhibitory to wild-type strains, it was
interesting to examine whether mutations in any nonessential
yeast gene(s) conferred increased sensitivity to ibuprofen. 
Remarkably, mutations in any of seven different genes
involved in tryptophan biosynthesis conferred enhanced
sensitivity to ibuprofen [5]. It is important to note that this
does not indicate that ibuprofen inhibits tryptophan biosynthe-
sis - all of these strains are viable on rich media - but that
loss of tryptophan synthesis coupled with the inhibitory
effects of ibuprofen on another molecule is toxic. In fact,
given the way this experiment was done, the existence of a
deletion strain that is synthetically lethal or synthetically less
viable with this set of strains could potentially identify the
direct target of ibuprofen toxicity in yeast. Alternatively,
overexpression-cloning could potentially identify the same
molecule as an ibuprofen-resistant transformant.
Targeting of sphingolipid synthesis by
dihydromotuporamine C 
Using a genetic arraying method, Baetz and co-workers [6],
screened 5,000 heterozygous yeast mutants for sensitivity
to dihydromotuporamine C, a compound used in preclinical
development as an inhibitor of metastasis. These investigators
did not exclude sick strains and identified 21 heterozygous
mutants that exhibited the greatest drug sensitivity. Trans-
ferring the 21 identified strains to liquid cultures with and
without drugs, they established that mutants heterozygous for
two steps in sphingolipid metabolism were the most sensitive
to dihydromotuporamine C. Turning to a candidate-gene
approach, they then discovered four additional strains
heterozygous for genes involved in sphingolipid metabolism
that were drug-sensitive. Because, additionally, the drug
reduced ceramide production in wild-type yeast and addition
of 50 nM ceramide protected human breast carcinoma cell line
MDA-231 from the drug, it appears that dihydromotupor-
amine C targets sphingolipid biosynthesis directly.
Rediscovery of rRNA processing as a target of
5-fluorouracil 
Using the barcoding method and a collection of 3,500 hetero-
zygous yeast diploid strains, Lum and colleagues [7]
screened 78 different drugs, the majority of which are
approved by the US Food and Drug Administration (FDA)
and are considered to have well-characterized targets.
Among these drugs was the cancer chemotherapy agent
5-fluorouracil, which was shown more than 30 years ago to
inhibit rRNA processing [16]. Despite extensive studies of
the drug’s mechanism of action in fungal [17], fly [18] and
human [16] systems, this information was nearly, but not
entirely, forgotten [19] as investigators focused on the potential
for 5-fluorouracil to function as a pro-drug of 5-fluoro-
dUMP, a potent inhibitor of thymidylate synthetase [20].
When Lum and colleagues tested heterozygous yeast strains
for sensitivity to 5-fluorouracil, they found eight strains
that were more sensitive than thymidylate synthetase
heterozygotes; at least seven of these mutants are defective
in rRNA processing, a result that not only reinvigorates
studies of the mechanism of action of 5-fluorouracil but also
suggests a number of new potential cancer targets. 
A new type of structure-activity relationship analysis
Quantitative structure-activity relationship (QSAR) analysis
is performed when a series of defined alterations in a small
molecule are correlated with the read-out of an in vitro or
in vivo assay of drug efficacy. When Giaever and co-workers
[8] screened 10 different drugs against 5,900 heterozygous
yeast strains by the barcoding method, they were surprised
to find that dyclonine, fenpropimorph, and alverine citrate,
which are described as an anesthetic, an agricultural anti-
fungal, and a muscle relaxant, respectively, have nearly
identical profiles of haploinsufficiency, with erg24, set6 and
tvp18 heterozygotes being most sensitive. Furthermore,
these investigators realized that the three drugs share a core
substructure that may provide the genetic basis for their
action. The haploinsufficiency profile can be considered an
exquisitely sensitive qualitative (rather than quantitative)
structure-activity relationship that maps chemical properties
not onto pharmacological potencies but onto pathways. The
degree to which the shared pathways in yeast underlie
target or off-target effects in the use of these drugs can now
be investigated.
In conclusion, although many high-throughput chemical
screening methods were developed for enzyme-target-based
assays, the parallelization of genetic and genomic methods have
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previously unanticipated scales. As with other areas of
genomics, the major challenge of chemical genomics is not
to extend the number of experiments to the factorial limit of
compounds, concentrations and strains, but rather to do the
most penetrating validation and mechanistic experiments to
extract the greatest insight from primary screens. Both
genetic-array-based and barcode-based methods can suffer
from systematic artifacts in which a particular deletion strain
might have been misidentified or might contain unintended
additional genetic changes that are or are not linked to the
intended deletion. Thus, as more experiments are performed
with existing yeast genomic libraries, accessible databases
should be archived with the detailed findings of previous
screens. Finally, standing on the shoulders of the yeast
community, investigators developing mutant resources in
Escherichia coli [21], Neurospora crassa [22] and vertebrate
cells are advancing genetic array [23] and barcode [24,25]
methods for functional screens that will allow chemistry to
interact with genomics across more branches of the tree of life.
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